我们的网站为什么显示成这样？

可能因为您的浏览器不支持样式，您可以更新您的浏览器到最新版本，以获取对此功能的支持，访问下面的网站，获取关于浏览器的信息：

|本期目录/Table of Contents|

间羟胺对感染性休克患者血压和肾脏功能的影响(PDF)

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2007年第6期
页码:
709-712
栏目:
临床研究
出版日期:
2007-12-20

文章信息/Info

Title:
Effect of metaraminol on arterial blood pressure and renal function in patients with septic shock
作者:
侯立朝; 朱萧玲; 熊利泽; 王雅丽; 胡文能
第四军医大学西京医院麻醉科，陕西 西安710032
Author(s):
HOU Li-chao;  ZHU Xiao-ling;  XIONG Li-ze;  WANG Ya-li;  HU Wen-neng
Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University. Xi'an, 710032, Shaanxi, China
关键词:
间羟胺; 感染性休克; 肾脏功能
Keywords:
metaraminol;  septic shock;  renal function
分类号:
R971.93；R631.4；R334.1
DOI:
-
文献标识码:
A
摘要:
目的 观察间羟胺对感染性休克患者血压、心率和肾脏功能的影响。方法 根据病情相近、病因相同、年龄相仿的原则收集1995年以来在我科ICU接受治疗的感染性休克患者70例。所有患者在休克发生后，均根据病情变化随时调整间羟胺用量，以维持血压稳定。然后根据临床使用间羟胺剂量的大小，将患者分成3组：小剂量组［A组，n=23，最大泵速为0.5~5 μg/(kg·min)］、中剂量组［B组，n=23，最大泵速为6~10 μg/(kg·min)］、大剂量组［C组，n=24，最大泵速为>11 μg/(kg·min)］。在治疗前对患者进行APACHE III评分，记录其血压、心率变化及尿量、BUN（血尿素氮）、CRE（肌酐）、尿ALB（白蛋白）和β2MG（β2微球蛋白）定量等肾功指标变化。 结果 抗休克治疗前，B组患者的APACHE III评分显著高于A组，但低于C组（P<0.01），说明3组患者的病情依次加重；所有患者BUN、CRE、尿ALB和β2MG定量均异常升高，但组间差异无统计学意义；抗休克治疗开始后，患者尿量、BUN、CRE及尿ALB和β2MG定量也逐步恢复（与治疗前相比，均P<0.01），但组间各指标随时间变化差异无统计学意义。结论 间羟胺用于感染性休克时，患者肾功的恢复与血流动力学的稳定相关，而与间羟胺剂量的关系不大。
Abstract:
AIM To study the effect of metaraminol on the renal function in the patients with septic shock. METHODS Seventy patients with septic shock, who had been admitted into ICU of Department of Anesthesiology, Xijing Hospital since 1995 were enrolled in this study. The dosage of metaraminol had been adjusted to maintain the stability of arterial blood pressure for all the patients with septic shock according to the changes in their conditions. Based on the dosage of metaraminol used clinically and our experiences, all the patients were divided into three groups: Group A had 23 cases with the biggest infusing rate of 0.5~5 μg/(kg·min) during antishock therapy, Group B had 23 cases with the biggest infusing rate of 6~10 μg/(kg·min), and Group C had 24 cases with the biggest infusing rate of >11 μg/(kg·min). APACHE III scoring was made for all the patients before the antishock therapy, and the changes in arterial blood pressure, heart rate (HR), urinary output, blood urea nitrogen (BUN), creatinine (CRE), urinary albumin (ALB) and β2microglobulin (β2MG) were recorded. RESULTS Before the antishock therapy, the APACHE III scoring in Group B was higher than that in Group A, but lower than that in Group C (P<0.01). The levels of BUN, CRE, urine ALB and β2MG output were abnormally high in all the patients, but with no statistical significance among the three groups. After the antishock therapy, the urine output, BUN, CRE, urine ALB and β2MG output gradually decreased compared with those before treatment (P<0.01) but with no statistical significance among the three groups. CONCLUSION Metaraminol promotes the restoration of the abnormal renal function in patients with septic shock, which is related to the hemodynamic stability and not the dosage of metaraminol used.

参考文献/References

［1］ Hurford WE. 危重症监测治疗手册 ［M］. 王俊科，郑斯聚，盛卓人，主译. 第3版.沈阳：辽宁科学技术出版社，2001：124.

［2］ Boffa JJ, Arendshorst WJ. Maintenance of renal vascular reactivity contributes to acute renal failure during endotoxemic shock［J］. J Am Soc Nephrol, 2005, 16(1): 117-124.

［3］ Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study［J］. JAMA, 2005, 294(7): 813-818.

［4］ Holmes CL. Vasoactive drugs in the intensive care unit［J］. Curr Opin Crit Care, 2005, 11(5): 413-417.

［5］ Bellomo R, Giantomasso DD. Noradrenaline and the kidney: friends or foes? ［J］. Crit Care, 2001, 5(6): 294-298.

［6］ Schetz M. Vasopressors and the kidney［J］. Blood Purif, 2002, 20(3):243-251

［7］ Lee RW, Di Giantomasso D, May C, et al. Vasoactive drugs and the kidney［J］. Best Pract Res Clin Anaesthesiol, 2004, 18(1): 53-74.

［8］ Natalini G, Schivalocchi V, Rosano A, et al. Norepinephrine and metaraminol in septic shock: a comparison of the hemodynamic effects［J］. Intensive Care Med, 2005, 31(5):634-637.

［9］ 康萍，马培龙，陆淼. β2微球蛋白在糖尿病早期肾损害中的意义［J］. 中国医药研究, 2005， 3(3):186.

［10］张培毅，徐富，兰继承，等. 尿白蛋白、尿β2微球蛋白、TammHorsfall蛋白联合检测对早期糖尿病肾病的诊断价值［J］. 中华医学丛刊, 2004, 4(4): 6-7.

备注/Memo

备注/Memo:
收稿日期：2006-04-18.通讯作者：熊利泽，主任医师，博士,主要从事中枢神经保护研究 Email:lxiong@fmmu.edu.cn 作者简介：侯立朝，副主任医师，博士 Email：hou2001@fmmu.edu.cn
更新日期/Last Update: